vs

Side-by-side financial comparison of Cellectis S.A. (CLLS) and Digimarc CORP (DMRC). Click either name above to swap in a different company.

Cellectis S.A. is the larger business by last-quarter revenue ($9.5M vs $8.9M, roughly 1.1× Digimarc CORP). Digimarc CORP runs the higher net margin — -47.2% vs -265.9%, a 218.7% gap on every dollar of revenue. On growth, Cellectis S.A. posted the faster year-over-year revenue change (375.0% vs 2.9%). Cellectis S.A. produced more free cash flow last quarter ($27.6M vs $895.0K).

Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina.

Digimarc Corporation is a provider of enterprise software and services. The company's software, which includes digital identifiers, is designed to address counterfeiting, product authenticity, recycling accuracy, and supply chain traceability. Digimarc products are created for multiple industries such as apparel, consumer packaged goods, health and beauty, and automotive.

CLLS vs DMRC — Head-to-Head

Bigger by revenue
CLLS
CLLS
1.1× larger
CLLS
$9.5M
$8.9M
DMRC
Growing faster (revenue YoY)
CLLS
CLLS
+372.1% gap
CLLS
375.0%
2.9%
DMRC
Higher net margin
DMRC
DMRC
218.7% more per $
DMRC
-47.2%
-265.9%
CLLS
More free cash flow
CLLS
CLLS
$26.7M more FCF
CLLS
$27.6M
$895.0K
DMRC

Income Statement — Q2 FY2024 vs Q4 FY2025

Metric
CLLS
CLLS
DMRC
DMRC
Revenue
$9.5M
$8.9M
Net Profit
$-25.3M
$-4.2M
Gross Margin
63.5%
Operating Margin
-181.1%
-48.2%
Net Margin
-265.9%
-47.2%
Revenue YoY
375.0%
2.9%
Net Profit YoY
-51.9%
51.4%
EPS (diluted)
$-0.28
$-0.18

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLLS
CLLS
DMRC
DMRC
Q4 25
$8.9M
Q3 25
$7.6M
Q2 25
$8.0M
Q1 25
$9.4M
Q4 24
$8.7M
Q3 24
$9.4M
Q2 24
$9.5M
$10.4M
Q1 24
$9.9M
Net Profit
CLLS
CLLS
DMRC
DMRC
Q4 25
$-4.2M
Q3 25
$-8.2M
Q2 25
$-8.2M
Q1 25
$-11.7M
Q4 24
$-8.6M
Q3 24
$-10.8M
Q2 24
$-25.3M
$-9.3M
Q1 24
$-10.3M
Gross Margin
CLLS
CLLS
DMRC
DMRC
Q4 25
63.5%
Q3 25
58.3%
Q2 25
58.8%
Q1 25
65.0%
Q4 24
60.8%
Q3 24
62.4%
Q2 24
66.1%
Q1 24
62.5%
Operating Margin
CLLS
CLLS
DMRC
DMRC
Q4 25
-48.2%
Q3 25
-109.7%
Q2 25
-105.2%
Q1 25
-128.9%
Q4 24
-105.1%
Q3 24
-120.4%
Q2 24
-181.1%
-96.2%
Q1 24
-109.2%
Net Margin
CLLS
CLLS
DMRC
DMRC
Q4 25
-47.2%
Q3 25
-106.9%
Q2 25
-102.6%
Q1 25
-125.2%
Q4 24
-99.9%
Q3 24
-113.9%
Q2 24
-265.9%
-89.3%
Q1 24
-104.0%
EPS (diluted)
CLLS
CLLS
DMRC
DMRC
Q4 25
$-0.18
Q3 25
$-0.38
Q2 25
$-0.38
Q1 25
$-0.55
Q4 24
$-0.40
Q3 24
$-0.50
Q2 24
$-0.28
$-0.43
Q1 24
$-0.50

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLLS
CLLS
DMRC
DMRC
Cash + ST InvestmentsLiquidity on hand
$149.0M
$12.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$148.6M
$40.2M
Total Assets
$407.1M
$53.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLLS
CLLS
DMRC
DMRC
Q4 25
$12.9M
Q3 25
$12.6M
Q2 25
$16.1M
Q1 25
$21.6M
Q4 24
$28.7M
Q3 24
$33.7M
Q2 24
$149.0M
$41.5M
Q1 24
$48.9M
Stockholders' Equity
CLLS
CLLS
DMRC
DMRC
Q4 25
$40.2M
Q3 25
$41.4M
Q2 25
$46.5M
Q1 25
$50.0M
Q4 24
$61.4M
Q3 24
$70.2M
Q2 24
$148.6M
$77.2M
Q1 24
$84.5M
Total Assets
CLLS
CLLS
DMRC
DMRC
Q4 25
$53.0M
Q3 25
$55.4M
Q2 25
$60.7M
Q1 25
$66.5M
Q4 24
$75.8M
Q3 24
$85.0M
Q2 24
$407.1M
$93.4M
Q1 24
$99.7M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLLS
CLLS
DMRC
DMRC
Operating Cash FlowLast quarter
$28.9M
$991.0K
Free Cash FlowOCF − Capex
$27.6M
$895.0K
FCF MarginFCF / Revenue
290.5%
10.0%
Capex IntensityCapex / Revenue
13.2%
1.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-12.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLLS
CLLS
DMRC
DMRC
Q4 25
$991.0K
Q3 25
$-2.6M
Q2 25
$-4.7M
Q1 25
$-5.5M
Q4 24
$-4.2M
Q3 24
$-7.1M
Q2 24
$28.9M
$-6.8M
Q1 24
$-8.4M
Free Cash Flow
CLLS
CLLS
DMRC
DMRC
Q4 25
$895.0K
Q3 25
$-2.8M
Q2 25
$-4.9M
Q1 25
$-5.5M
Q4 24
$-4.2M
Q3 24
$-7.2M
Q2 24
$27.6M
$-6.9M
Q1 24
$-8.5M
FCF Margin
CLLS
CLLS
DMRC
DMRC
Q4 25
10.0%
Q3 25
-36.9%
Q2 25
-61.0%
Q1 25
-59.1%
Q4 24
-49.1%
Q3 24
-75.7%
Q2 24
290.5%
-66.1%
Q1 24
-85.8%
Capex Intensity
CLLS
CLLS
DMRC
DMRC
Q4 25
1.1%
Q3 25
2.9%
Q2 25
2.5%
Q1 25
0.6%
Q4 24
0.2%
Q3 24
0.7%
Q2 24
13.2%
0.3%
Q1 24
1.1%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLLS
CLLS

Segment breakdown not available.

DMRC
DMRC

Subscription$5.3M60%
The Government$3.6M41%

Related Comparisons